| Year |
Citation |
Score |
| 2023 |
Scarborough JA, Eschrich SA, Torres-Roca J, Dhawan A, Scott JG. Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. Npj Precision Oncology. 7: 38. PMID 37076665 DOI: 10.1038/s41698-023-00375-y |
0.311 |
|
| 2020 |
Pérez-Morales J, Tunali I, Stringfield O, Eschrich SA, Balagurunathan Y, Gillies RJ, Schabath MB. Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening. Scientific Reports. 10: 10528. PMID 32601340 DOI: 10.1038/S41598-020-67378-8 |
0.385 |
|
| 2020 |
Encarnacion J, Ortiz-Sanchez C, Dutil J, Torres-Gracia W, Eschrich S, Pilon-Thomas S, Matta JL. Abstract LB-359: Gene expression profile and tumor infiltrating lymphocytes in Hispanic women with breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-359 |
0.354 |
|
| 2020 |
Tunali I, Tan Y, Gray JE, Katsoulakis E, Eschrich SA, Saller J, Boyle T, Qi J, Guvenis A, Gillies RJ, Schabath MB. Abstract 5806: Hypoxia-related radiomics predict checkpoint blockade immunotherapy response of non-small cell lung cancer patients Cancer Research. 80: 5806-5806. DOI: 10.1158/1538-7445.Am2020-5806 |
0.398 |
|
| 2019 |
Mohammadi H, Prince A, Figura NB, Peacock JS, Fernandez DC, Montejo ME, Chon HS, Wenham RM, Eschrich SA, Torres-Roca JF, Ahmed KA. Utilizing the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated with Adjuvant Radiotherapy. International Journal of Radiation Oncology, Biology, Physics. PMID 31759077 DOI: 10.1016/J.Ijrobp.2019.11.013 |
0.388 |
|
| 2019 |
Saller J, Seydafkan S, Shahid M, Gadara M, Cives M, Eschrich SA, Boulware D, Strosberg JR, Aejaz N, Coppola D. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Cancer Genomics & Proteomics. 16: 309-318. PMID 31467225 DOI: 10.21873/Cgp.20136 |
0.302 |
|
| 2019 |
Ahmed KA, Liveringhouse CL, Mills MN, Figura NB, Grass GD, Washington IR, Harris EE, Czerniecki BJ, Blumencranz PW, Eschrich SA, Scott JG, Diaz R, Torres-Roca JF. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. Ebiomedicine. PMID 31416721 DOI: 10.1016/J.Ebiom.2019.08.019 |
0.305 |
|
| 2019 |
Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Fellows KM, ... ... Eschrich SA, et al. Proteogenomic landscape of squamous cell lung cancer. Nature Communications. 10: 3578. PMID 31395880 DOI: 10.1038/S41467-019-11452-X |
0.402 |
|
| 2019 |
Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology. PMID 31257184 DOI: 10.1016/J.Chembiol.2019.06.003 |
0.343 |
|
| 2019 |
Dutil J, Chen Z, Monteiro AN, Teer JK, Eschrich SA. An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. Cancer Research. PMID 30894373 DOI: 10.1158/0008-5472.Can-18-2747 |
0.362 |
|
| 2019 |
Gordian E, Welsh EA, Gimbrone N, Siegel EM, Shibata D, Creelan BC, Cress WD, Eschrich SA, Haura EB, Muñoz-Antonia T. Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. Oncotarget. 10: 810-824. PMID 30783512 DOI: 10.18632/Oncotarget.26574 |
0.434 |
|
| 2019 |
Koomen DC, Meads MB, Magaletti DM, Guingab JD, Oliveira PS, Fang B, Izumi V, Renatino-Canevarolo R, Sudalagunta PR, Silva M, Alugubelli R, De Avilla G, Tungeskiv A, Welsh EA, Meke LE, ... ... Eschrich SA, et al. Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma Blood. 134: 5534-5534. DOI: 10.1182/Blood-2019-132001 |
0.326 |
|
| 2019 |
Morales JP, Tunali I, Stringfield O, Eschrich S, Balagurunathan Y, Gillies R, Schabath M. OA02.08 Peritumoral and Intratumoral Radiomic Features Identify Aggressive Screen-Detected Early-Stage Lung Cancers Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.09.030 |
0.343 |
|
| 2019 |
Tunali I, Tan Y, Gray JE, Eschrich S, Guvenis A, Gillies R, Schabath M. OA02.05 Clinical-Radiomic Models Predict Overall Survival Among Non-Small Cell Lung Cancer Patients Treated with Immunotherapy Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.09.027 |
0.381 |
|
| 2018 |
Ahmed KA, Scott JG, Arrington JA, Naghavi AO, Grass GD, Perez BA, Caudell JJ, Berglund AE, Welsh EA, Eschrich SA, Dilling TJ, Torres-Roca JF. Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29733909 DOI: 10.1016/J.Jtho.2018.04.027 |
0.325 |
|
| 2018 |
Welsh EA, Stewart PA, Chambers MC, Zhang G, Fang B, Eschrich SA, Koomen JM, Haura EB. Abstract 2708: Imputation-free analysis of high throughput TMT proteomics of 116 lung squamous samples Cancer Research. 78: 2708-2708. DOI: 10.1158/1538-7445.Am2018-2708 |
0.349 |
|
| 2017 |
Teer JK, Zhang Y, Chen L, Welsh EA, Cress WD, Eschrich SA, Berglund AE. Evaluating somatic tumor mutation detection without matched normal samples. Human Genomics. 11: 22. PMID 28870239 DOI: 10.1186/S40246-017-0118-2 |
0.31 |
|
| 2017 |
Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS. Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility. Jmir Research Protocols. 6: e45. PMID 28320689 DOI: 10.2196/Resprot.7289 |
0.319 |
|
| 2017 |
Kamath VP, Torres-Roca JF, Eschrich SA. Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. International Journal of Genomics. 2017: 6576840. PMID 28280724 DOI: 10.1155/2017/6576840 |
0.35 |
|
| 2017 |
Berglund AE, Welsh EA, Eschrich SA. Characteristics and Validation Techniques for PCA-Based Gene-Expression Signatures. International Journal of Genomics. 2017: 2354564. PMID 28265563 DOI: 10.1155/2017/2354564 |
0.308 |
|
| 2017 |
Stewart PA, Fang B, Slebos RJ, Zhang G, Borne AL, Fellows K, Teer JK, Chen YA, Welsh E, Eschrich SA, Haura EB, Koomen JM. Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. Proteomics. PMID 28195392 DOI: 10.1002/Pmic.201600300 |
0.302 |
|
| 2017 |
Siegel EM, Eschrich SA, Berglund AE, Ajidahun AO, Magliocco AM, Putney R, Riggs B, Moughan J, Hoffe SE, Simko J, Ajani JA, Guha C, Okawara GS, Clouse JW, Becker MJ, et al. Methylomic classifiers of anal cancer outcomes: An NRG Oncology / RTOG 98-11 tissue study. Journal of Clinical Oncology. 35: 588-588. DOI: 10.1200/Jco.2017.35.4_Suppl.588 |
0.356 |
|
| 2017 |
Sumi NJ, Fang B, Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC Cancer Research. 77: 221-221. DOI: 10.1158/1538-7445.Am2017-221 |
0.374 |
|
| 2017 |
Stewart PA, Slebos RJ, Welsh EA, Cen L, Zhang Y, Chen Z, Cheng C, Pettersson F, Berglund A, Zhang G, Fang B, Izumi V, Yoder S, Fellows K, Chen A, ... ... Eschrich SA, et al. Abstract 205: Underlying mechanisms of genome-proteome discordance in squamous cell lung cancer Cancer Research. 77: 205-205. DOI: 10.1158/1538-7445.Am2017-205 |
0.365 |
|
| 2017 |
Pettersson F, Stewart PA, Slebos RJ, Welsh EA, Cen L, Zhang Y, Chen Z, Cheng C, Zhang G, Fang B, Izumi V, Yoder S, Fellows K, Chen YA, Teer JK, ... Eschrich S, et al. Abstract 1565: OnPLS-based integrative proteogenomics analysis of lung squamous cell cancer Cancer Research. 77: 1565-1565. DOI: 10.1158/1538-7445.Am2017-1565 |
0.369 |
|
| 2016 |
Kim JY, Stewart PA, Borne AL, Fang B, Welsh EA, Chen YA, Eschrich SA, Koomen JM, Haura EB. Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. Proteomes. 4: 16. PMID 28154798 DOI: 10.3390/Proteomes4020016 |
0.344 |
|
| 2016 |
Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, ... ... Eschrich SA, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. The Lancet. Oncology. PMID 27993569 DOI: 10.1016/S1470-2045(16)30648-9 |
0.324 |
|
| 2016 |
Jiang K, Neill K, Cowden D, Klapman J, Eschrich S, Pimiento J, Malafa MP, Coppola D. Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Applied Immunohistochemistry & Molecular Morphology : Aimm. PMID 27941559 DOI: 10.1097/Pai.0000000000000464 |
0.328 |
|
| 2016 |
Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, et al. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. PMID 27756884 DOI: 10.18632/Oncotarget.12672 |
0.354 |
|
| 2016 |
Ahmed KA, Berglund AE, Welsh EA, Naghavi AO, Perez BA, Dilling TJ, Eschrich SA, Torres-Roca JF. Differences in the Radiosensitivity Index (RSI) Between Lung Metastases Based Upon Primary Histology. International Journal of Radiation Oncology, Biology, Physics. 96: S68. PMID 27675988 DOI: 10.1016/J.Ijrobp.2016.06.173 |
0.305 |
|
| 2016 |
Pimiento JM, Neill KG, Henderson-Jackson E, Eschrich SA, Chen DT, Husain K, Shibata D, Coppola D, Malafa MP. Knockdown of CSE1L Gene in Colorectal Cancer Reduces Tumorigenesis in Vitro. The American Journal of Pathology. PMID 27521996 DOI: 10.1016/J.Ajpath.2016.06.016 |
0.331 |
|
| 2016 |
Schabath MB, Massion PP, Thompson ZJ, Eschrich SA, Balagurunathan Y, Goldof D, Aberle DR, Gillies RJ. Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. Plos One. 11: e0159880. PMID 27509046 DOI: 10.1371/Journal.Pone.0159880 |
0.38 |
|
| 2016 |
Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB. Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer. Molecular Cancer Research : McR. PMID 27422710 DOI: 10.1158/1541-7786.Mcr-15-0506 |
0.322 |
|
| 2016 |
Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Plos One. 11: e0147344. PMID 26789630 DOI: 10.1371/Journal.Pone.0147344 |
0.335 |
|
| 2016 |
Strom TJC, Hoffe SE, Frakes JM, Fulp WJ, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Shridhar R, Torres-Roca J. Genomically adjusted radiation dose to predict for survival with adjuvant radiation in resectable pancreatic cancer. Journal of Clinical Oncology. 34: 240-240. DOI: 10.1200/Jco.2016.34.4_Suppl.240 |
0.379 |
|
| 2016 |
Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Hoffe SE, Frakes JM, Eschrich SA, Torres-Roca J. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes following SBRT. Journal of Clinical Oncology. 34: 239-239. DOI: 10.1200/Jco.2016.34.4_Suppl.239 |
0.311 |
|
| 2016 |
Peterman S, Fang B, Hoffmann M, Prakash A, Stewart PA, Liu R, Smith M, Johnson J, Eschrich S, Zhang G, Haura E, Koomen J. Abstract LB-140: Scaling discovery proteomics to large lung cancer cohorts using data independent acquisition Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-140 |
0.41 |
|
| 2015 |
Stewart PA, Parapatics K, Welsh EA, Müller AC, Cao H, Fang B, Koomen JM, Eschrich SA, Bennett KL, Haura EB. A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. Plos One. 10: e0142162. PMID 26539827 DOI: 10.1371/Journal.Pone.0142162 |
0.35 |
|
| 2015 |
Torres-Roca JF, Fulp WJ, Caudell JJ, Servant N, Bollet MA, van de Vijver M, Naghavi AO, Harris EE, Eschrich SA. Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. International Journal of Radiation Oncology, Biology, Physics. 93: 631-8. PMID 26461005 DOI: 10.1016/J.Ijrobp.2015.06.021 |
0.328 |
|
| 2015 |
Ahmed KA, Chinnaiyan P, Fulp WJ, Eschrich S, Torres-Roca JF, Caudell JJ. The radiosensitivity index predicts for overall survival in glioblastoma. Oncotarget. 6: 34414-22. PMID 26451615 DOI: 10.18632/Oncotarget.5437 |
0.382 |
|
| 2015 |
Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 117: 159-64. PMID 26235848 DOI: 10.1016/J.Radonc.2015.07.018 |
0.391 |
|
| 2015 |
Wang H, Schabath MB, Liu Y, Berglund AE, Bloom GC, Kim J, Stringfield O, Eikman EA, Klippenstein DL, Heine JJ, Eschrich SA, Ye Z, Gillies RJ. Semiquantitative Computed Tomography Characteristics for Lung Adenocarcinoma and Their Association With Lung Cancer Survival. Clinical Lung Cancer. PMID 26077095 DOI: 10.1016/J.Cllc.2015.05.007 |
0.341 |
|
| 2015 |
Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca JF. Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. International Journal of Radiation Oncology, Biology, Physics. 92: 837-42. PMID 25838188 DOI: 10.1016/J.Ijrobp.2015.01.036 |
0.396 |
|
| 2015 |
Pidala J, Bloom GC, Eschrich S, Sarwal M, Enkemann S, Betts BC, Beato F, Yoder S, Anasetti C. Tolerance associated gene expression following allogeneic hematopoietic cell transplantation. Plos One. 10: e0117001. PMID 25774806 DOI: 10.1016/J.Bbmt.2011.12.067 |
0.301 |
|
| 2015 |
Grove O, Berglund AE, Schabath MB, Aerts HJ, Dekker A, Wang H, Velazquez ER, Lambin P, Gu Y, Balagurunathan Y, Eikman E, Gatenby RA, Eschrich S, Gillies RJ. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. Plos One. 10: e0118261. PMID 25739030 DOI: 10.1371/Journal.Pone.0118261 |
0.337 |
|
| 2015 |
Ahmed KA, Fulp WJ, Berglund AE, Hoffe SE, Dilling TJ, Eschrich SA, Shridhar R, Torres-Roca J. Differences between colon cancer primaries and metastases utilizing a molecular assay for tumor radiosensitivity and implications for potential oligometastatic SBRT patient selection. Journal of Clinical Oncology. 33: 569-569. DOI: 10.1200/Jco.2015.33.3_Suppl.569 |
0.415 |
|
| 2015 |
Strom TJC, Hoffe SE, Coppala D, Springett GM, Malafa MP, Eschrich SA, Torres-Roca J, Shridhar R. Radiosensensitivity index prognostic for survival with adjuvant radiation in resectable pancreatic cancer. Journal of Clinical Oncology. 33: 398-398. DOI: 10.1200/Jco.2015.33.3_Suppl.398 |
0.409 |
|
| 2015 |
Stewart PA, Li J, Fisher KJ, Dhungana S, Stewart D, Sumner S, Gardner E, Poirier J, Rudin CM, Welsh EA, Eschrich S, Chen A, Haura EB. Abstract 3752: Integrating proteomics and metabolomics characterizes active pathways and potential drug targets in small cell lung cancer Cancer Research. 75: 3752-3752. DOI: 10.1158/1538-7445.Am2015-3752 |
0.358 |
|
| 2015 |
Martinez M, Fang B, Li J, Chen YA, Brantley S, Guan W, Kinose F, Welsh E, Eschrich SA, Haura EB, Koomen JM. Abstract 1817: Quantitative proteomics identifies unique signaling phenotypes in NSCLC Cancer Research. 75: 1817-1817. DOI: 10.1158/1538-7445.Am2015-1817 |
0.39 |
|
| 2015 |
Ahmed KA, Fulp WJ, Diaz R, Berglund AE, Eschrich SA, Torres-Roca JF. Differences Between Breast Cancer Primaries and Metastases Utilizing a Molecular Assay for Tumor Radiosensitivity Suggest Implications for Radiation Dose Selection International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.329 |
0.347 |
|
| 2015 |
Torres-Roca JF, Teer J, Jin W, Hoffe SE, Eschrich SA. Genetic Characterization of Radioresistance in Colorectal Cancer International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.296 |
0.318 |
|
| 2014 |
Siegel EM, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Moughan J, Ajani J, Magliocco A, Elahi A, Hoffe S, Shibata D. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Diseases of the Colon and Rectum. 57: 941-57. PMID 25003289 DOI: 10.1097/Dcr.0000000000000160 |
0.39 |
|
| 2014 |
Balagurunathan Y, Kumar V, Gu Y, Kim J, Wang H, Liu Y, Goldgof DB, Hall LO, Korn R, Zhao B, Schwartz LH, Basu S, Eschrich S, Gatenby RA, Gillies RJ. Test-retest reproducibility analysis of lung CT image features. Journal of Digital Imaging. 27: 805-23. PMID 24990346 DOI: 10.1007/S10278-014-9716-X |
0.304 |
|
| 2014 |
Kim J, Fang B, Welsh EA, Kinose F, Li J, Eschrich SA, Koomen JM, Haura EB. Abstract A31: Activity-based protein profiling reveals adaptive response to pharmacological MEK inhibition in KRAS mutant non-small cell lung cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A31 |
0.375 |
|
| 2014 |
Kurtyka CA, Chen L, Schabath MB, Chen D, Brazelle W, Welsh EA, Berglund AE, Eschrich SA, Gray JE, Haura EB, Cress WD. Abstract 914: Development of a prognostic and predictive E2F signature in formalin-fixed, paraffin-embedded early-stage non-small cell lung cancer samples Cancer Research. 74: 914-914. DOI: 10.1158/1538-7445.Am2014-914 |
0.416 |
|
| 2014 |
Engel BE, Schabath MB, Thompson ZJ, Eschrich SA, Brantley SG, Belock AR, Berglund A, Gray JE, Beg AA, Haura EB, Cress WD. Abstract 4159: Characterization of three recurring STK11/LKB1 mutants in lung adenocarcinoma Cancer Research. 74: 4159-4159. DOI: 10.1158/1538-7445.Am2014-4159 |
0.379 |
|
| 2014 |
Schabath MB, Massion PP, Thompson ZJ, Balagurunathan Y, Goldof D, Eschrich SA, Gillies RJ. Abstract 3250: Survival of patients with incident lung cancer following screening by computed tomography in the National Lung Screening Trial Cancer Research. 74: 3250-3250. DOI: 10.1158/1538-7445.Am2014-3250 |
0.388 |
|
| 2014 |
Fang B, Wood ER, Li J, Chen YA, Brantley SG, Kinose F, Guan W, Myers AR, Eschrich SA, Haura EB, Koomen JM. Abstract 1614: Kinases in lung squamous cell carcinoma and inhibitor matching using quantitative activity-based protein profiling Cancer Research. 74: 1614-1614. DOI: 10.1158/1538-7445.Am2014-1614 |
0.372 |
|
| 2014 |
Shridhar R, Strom T, Springett GM, Hoffe SE, Coppola D, Malafa MP, Eschrich SA, Torres-Roca J. Radiosensensitivity Index Shows Promise for Predicting Outcomes With Adjuvant Radiation in Resected Pancreatic Cancer Patients International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.684 |
0.343 |
|
| 2014 |
Torres-Roca JF, Fulp WJ, Naghavi AO, Servant N, Bollet M, Vijver MJvd, Harris EE, Eschrich SA. Integrating a Molecular Signature of Intrinsic Radiosensitivity Into the Classification of Breast Cancer International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.675 |
0.303 |
|
| 2014 |
Creelan B, Eschrich SA, Fulp WJ, Torres-Roca JF. A Gene Expression Platform to Predict Benefit From Adjuvant External Beam Radiation in Resected Non-Small Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.455 |
0.312 |
|
| 2013 |
Caudell JJ, Eschrich SA, Torres-Roca JF. Personalized medicine for radiation therapy. Personalized Medicine. 10: 107-110. PMID 29758841 DOI: 10.2217/Pme.12.120 |
0.404 |
|
| 2013 |
Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, ... ... Eschrich S, et al. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Molecular Systems Biology. 9: 705. PMID 24189400 DOI: 10.1038/Msb.2013.61 |
0.326 |
|
| 2013 |
Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 110: 12414-9. PMID 23836654 DOI: 10.1073/Pnas.1220674110 |
0.398 |
|
| 2013 |
Siegel EM, Berglund A, Riggs B, Eschrich S, Kristen M, Ajidahun A, Shibata D, Brown KD. Abstract PR08: Identification of novel methylated genomic regions in invasive cervical cancer using a genome-wide approach Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-Pr08 |
0.311 |
|
| 2013 |
Kim J, Welsh EA, Fang B, Oguz U, Li J, Kinose F, Bronk C, Beg AA, Chen A, Eschrich S, Koomen J, Haura EB. Abstract 937: Dissection of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer cells. Cancer Research. 73: 937-937. DOI: 10.1158/1538-7445.Am2013-937 |
0.409 |
|
| 2013 |
Berglund AE, Welsh EA, Fenstermacher DA, Eschrich SA. Abstract 2905: Validation techniques for PCA-based gene expression signatures. Cancer Research. 73: 2905-2905. DOI: 10.1158/1538-7445.Am2013-2905 |
0.367 |
|
| 2013 |
Fang B, Li J, Chen YA, Eschrich SA, Myers AR, Haura EB, Koomen JM. Abstract 2483: Signaling phenotypes in non-small cell lung cancer and normal lung defined by kinase activity profiling and phosphoproteomics. Cancer Research. 73: 2483-2483. DOI: 10.1158/1538-7445.Am2013-2483 |
0.404 |
|
| 2013 |
Kurtyka CA, Chen D, Chen L, Brazelle W, Welsh EA, Berglund AE, Eschrich SA, Schabath MB, Haura EB, Cress WD. Abstract 2354: An E2F signature predicts benefit of adjuvant chemotherapy in early-stage non-small cell lung cancer. Cancer Research. 73: 2354-2354. DOI: 10.1158/1538-7445.Am2013-2354 |
0.403 |
|
| 2013 |
Kim J, Welsh EA, Fang B, Li J, Eschrich SA, Koomen J, Haura EB. Abstract A61: Characterization of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A61 |
0.398 |
|
| 2013 |
Torres-Roca J, Servant N, Bollet M, Eschrich S. Abstract P2-11-11: Clinical utility of a radiosensitivity molecular signature: Identification of breast cancer patients that benefit from RT boost dose Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-11-11 |
0.35 |
|
| 2013 |
Siegel E, Eschrich S, Winter K, Riggs B, Berglund A, Ajidahun A, Simko J, Ajani J, Magliocco A, Elahi A, Coppola D, Shibata D. 42. Epigenomic profiling of anal cancer: does size matter? An RTOG 98-11 specimen study Sexual Health. 10: 590-590. DOI: 10.1071/Shv10N6Ab42 |
0.359 |
|
| 2012 |
Eschrich SA, Fulp WJ, Pawitan Y, Foekens JA, Smid M, Martens JW, Echevarria M, Kamath V, Lee JH, Harris EE, Bergh J, Torres-Roca JF. Validation of a radiosensitivity molecular signature in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5134-43. PMID 22832933 DOI: 10.1158/1078-0432.Ccr-12-0891 |
0.338 |
|
| 2012 |
Torres-Roca JF, Fulp WJ, Pawitan Y, Foekens J, Smid M, Kamath V, Echevarria M, Lee J, Harris EE, Bergh J, Eschrich S. Abstract 678: Validation of a radiosensitivity molecular signature in breast cancer Cancer Research. 72: 678-678. DOI: 10.1158/1538-7445.Am2012-678 |
0.356 |
|
| 2012 |
Gordian E, Enkemann S, Eschrich S, Haura E, Munoz-Antonia T. Abstract 3395: TGFβ response signature in non-small cell lung carcinoma Cancer Research. 72: 3395-3395. DOI: 10.1158/1538-7445.Am2012-3395 |
0.43 |
|
| 2012 |
Haura EB, Yoshida T, Fang B, Stukalov A, Eschrich S, Welsh E, Colinge J, Koomen J, Superti-Furga G, Li J, Rix U, Zhang G, Kim J, Bennett K, Song L, et al. Abstract IA2: Network models in oncogene-addicted lung cancer Clinical Cancer Research. 18: IA2-IA2. DOI: 10.1158/1078-0432.12Aacriaslc-Ia2 |
0.363 |
|
| 2012 |
CANUL-REICH J, HALL LO, GOLDGOF DB, KORECKI JN, ESCHRICH S. ITERATIVE FEATURE PERTURBATION AS A GENE SELECTOR FOR MICROARRAY DATA International Journal of Pattern Recognition and Artificial Intelligence. 26: 1260003. DOI: 10.1142/S0218001412600038 |
0.334 |
|
| 2012 |
Barrett CW, Hill KE, Washington K, Motley AK, Stevenson TD, Bradley A, McDonough E, Choksi YA, Ning W, Parang B, Beauchamp RD, Yeatman TJ, Eschrich S, Chen X, Smith JJ, et al. Mo1601 Selenium and the Major Selenium Transporter Selenoprotein P Modify Colitis-Associated Carcinoma Gastroenterology. 142: S-639. DOI: 10.1016/S0016-5085(12)62456-1 |
0.311 |
|
| 2012 |
Pimiento JM, Coppola D, Zhang A, Husain K, Eschrich S, Chen D, Malafa MP. Targeting CSE1L in colorectal cancer Journal of the American College of Surgeons. 215: S127. DOI: 10.1016/J.Jamcollsurg.2012.06.328 |
0.33 |
|
| 2012 |
Smith JJ, Freeman TJ, Chen X, Deane NG, Washington MK, Revetta F, Roland JT, Eschrich S, Yeatman TJ, Beauchamp RD. A Smad4-modulated Wnt target gene expression profile identifies high-risk colorectal cancer patients Journal of the American College of Surgeons. 215: S30-S31. DOI: 10.1016/J.Jamcollsurg.2012.06.099 |
0.367 |
|
| 2011 |
Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, Cress WD. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. Plos One. 6: e24923. PMID 22046235 DOI: 10.1371/Journal.Pone.0024923 |
0.347 |
|
| 2011 |
Williams CS, Zhang B, Smith JJ, Jayagopal A, Barrett CW, Pino C, Russ P, Presley SH, Peng D, Rosenblatt DO, Haselton FR, Yang JL, Washington MK, Chen X, Eschrich S, et al. BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. The Journal of Clinical Investigation. 121: 4056-69. PMID 21911938 DOI: 10.1172/Jci44228 |
0.324 |
|
| 2011 |
Singh AB, Sharma A, Smith JJ, Krishnan M, Chen X, Eschrich S, Washington MK, Yeatman TJ, Beauchamp RD, Dhawan P. Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology. 141: 2140-53. PMID 21878201 DOI: 10.1053/J.Gastro.2011.08.038 |
0.342 |
|
| 2011 |
Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, et al. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Molecular & Cellular Proteomics : McP. 10: M110.005520. PMID 21846842 DOI: 10.1074/Mcp.M110.005520 |
0.319 |
|
| 2011 |
Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, ... ... Eschrich SA, et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics. Clinical Applications. 5: 383-96. PMID 21656910 DOI: 10.1002/Prca.201000115 |
0.348 |
|
| 2011 |
Dhawan P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD, Singh AB. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene. 30: 3234-47. PMID 21383692 DOI: 10.1038/Onc.2011.43 |
0.386 |
|
| 2011 |
Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y, Oguz U, Remily-Wood ER, Li J, Altiok S, Eschrich S, Koomen J, Haura EB. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity Journal of Proteome Research. 10: 305-319. PMID 21080693 DOI: 10.1021/Pr1006203 |
0.319 |
|
| 2011 |
Gillies RJ, Goldgof D, Hall L, Gatenby R, Kumar V, Gu Y, Basu S, Kim J, Gray J, Tockman M, Song D, Eschrich S. Abstract ED01-02: Imaging ‘omics in cancer detection Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-Ed01-02 |
0.372 |
|
| 2011 |
Siegel EM, Fulton A, Riggs B, Shibata D, Eschrich S, Sellers T. Abstract 1919: Baseline characteristics of colorectal cancer patients enrolled in the colorectal cancer outcomes, prognosis and epidemiology cohort (The COPE) study Epidemiology. 71: 1919-1919. DOI: 10.1158/1538-7445.Am2011-1919 |
0.352 |
|
| 2011 |
Henderson-Jackson E, Eschrich SA, Chen D, Yeatman TJ, Coppola D, Malafa MP. Abstract 1679: Increased expression of hCAS/CSE1L in colorectal cancer: Correlation with tumor progression Cancer Research. 71: 1679-1679. DOI: 10.1158/1538-7445.Am2011-1679 |
0.389 |
|
| 2011 |
Zhang G, Chen A, Song L, Fu J, Kinose F, Bai Y, Fang B, Li J, Eschrich S, Koomen J, Haura E. Abstract 1627: Proteome-wide analysis of echinoderm microtubule associated protein like 4 – anaplastic lymphoma kinase (EML4-ALK) network in lung cancer Cancer Research. 71: 1627-1627. DOI: 10.1158/1538-7445.Am2011-1627 |
0.377 |
|
| 2011 |
Mathur R, Schaffer JD, Land WH, Heine JJ, Eschrich S, Yeatman T. Evolutionary computation with noise perturbation and cluster analysis to discover biomarker sets Procedia Computer Science. 6: 153-158. DOI: 10.1016/J.Procs.2011.08.030 |
0.311 |
|
| 2010 |
Machida K, Eschrich S, Li J, Bai Y, Koomen J, Mayer BJ, Haura EB. Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling Plos One. 5. PMID 20976048 DOI: 10.1371/Journal.Pone.0013470 |
0.374 |
|
| 2010 |
Chen Y, Gruidl M, Remily-Wood E, Liu RZ, Eschrich S, Lloyd M, Nasir A, Bui MM, Huang E, Shibata D, Yeatman T, Koomen JM. Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. Journal of Proteome Research. 9: 4215-27. PMID 20590165 DOI: 10.1021/Pr1005197 |
0.344 |
|
| 2010 |
Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochemical Pharmacology. 80: 739-47. PMID 20361944 DOI: 10.1016/J.Bcp.2010.03.027 |
0.308 |
|
| 2010 |
Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Nature Chemical Biology. 6: 291-299. PMID 20190765 DOI: 10.1038/Nchembio.332 |
0.328 |
|
| 2010 |
Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 138: 958-68. PMID 19914252 DOI: 10.1053/J.Gastro.2009.11.005 |
0.401 |
|
| 2010 |
Krishnan M, Singh AB, Smith JJ, Sharma A, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P. HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene. 29: 305-12. PMID 19881542 DOI: 10.1038/Onc.2009.324 |
0.372 |
|
| 2010 |
Liu RZ, Fulton A, Ge W, Shibata D, Eschrich SA, Siegel EM. Abstract B94: An integrated database in colorectal cancer outcomes, prognosis, and epidemiology (The COPE database) Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-B94 |
0.353 |
|
| 2010 |
Shivers SC, Coppola D, Eschrich SA, Chen D, Shibata D, Yeatman TJ, Malafa MP. Abstract 4636: Increased expression of CSE1L/hCAS in colorectal cancer: Correlation with tumor progression Cancer Research. 70: 4636-4636. DOI: 10.1158/1538-7445.Am10-4636 |
0.416 |
|
| 2010 |
Singh AB, Smith JJ, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Beauchamp RD, Dhawan P. Abstract 2961: Expression of ZEB1, an E-cadherin repressor correlates with poor patient survival in colon cancer and mediates claudin-1 dependent repression of E-cadherin Cancer Research. 70: 2961-2961. DOI: 10.1158/1538-7445.Am10-2961 |
0.361 |
|
| 2010 |
Emmons M, Nair R, McLaughlin M, Eschrich S, Cress A, Hazlehurst L. Abstract 1547: Acquisition of resistance to the β1 integrin antagonist HYD1 correlates with decreased α4, α6, αV and β1 integrin expression and decreased adhesion to fibronectin, VCAM-1 and vitronectin Cancer Research. 70: 1547-1547. DOI: 10.1158/1538-7445.Am10-1547 |
0.309 |
|
| 2009 |
Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, et al. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7642-7651. PMID 19996206 DOI: 10.1158/1078-0432.Ccr-09-1431 |
0.383 |
|
| 2009 |
Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. International Journal of Radiation Oncology, Biology, Physics. 75: 489-96. PMID 19735873 DOI: 10.1016/J.Ijrobp.2009.06.014 |
0.332 |
|
| 2009 |
Santillan AA, Dinwoodie W, Yeatman TJ, Eschrich SA, Sullivan D, Rocha-Lima CS, Greenberg HM, Chodkiewicz C, Trotti A, Marcet J, Dessureault S, Legenne P, Wissel P, Tyagi P, Shibata D. 810 Molecular Predictors of Response to Neoadjuvant Topotecan and Radiation for Rectal Cancer: Correlative Study to a Phase I Trial Gastroenterology. 136: A-880. DOI: 10.1016/S0016-5085(09)64064-6 |
0.32 |
|
| 2008 |
Chen DT, Schell MJ, Chen JJ, Fulp WJ, Eschrich S, Yeatman T. A predictive risk probability approach for microarray data with survival as an endpoint. Journal of Biopharmaceutical Statistics. 18: 841-52. PMID 18781520 DOI: 10.1080/10543400802277967 |
0.336 |
|
| 2008 |
Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine. 14: 822-7. PMID 18641660 DOI: 10.1038/Nm.1790 |
0.391 |
|
| 2008 |
Li CG, Gruidl M, Eschrich S, McCarthy S, Wang HG, Alexandrow MG, Yeatman TJ. Insig2 is associated with colon tumorigenesis and inhibits Bax-mediated apoptosis. International Journal of Cancer. Journal International Du Cancer. 123: 273-82. PMID 18464289 DOI: 10.1002/Ijc.23510 |
0.362 |
|
| 2008 |
Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. Bmc Medical Genomics. 1: 13. PMID 18442402 DOI: 10.1186/1755-8794-1-13 |
0.364 |
|
| 2008 |
Eschrich S, Pramana J, Zhang H, Zhao H, Boulware D, Lee J, Bloom G, Yeatman T, Begg A, Torres-Roca J. A Gene Expression Assay to Predict Tumor Radiosensitivity International Journal of Radiation Oncology*Biology*Physics. 72: S244. DOI: 10.1016/J.Ijrobp.2008.06.630 |
0.323 |
|
| 2007 |
Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, Kong S, Sakthivel B, Xu H, Reichling T, Azhar M, ... ... Eschrich S, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biology. 8: R131. PMID 17615082 DOI: 10.1186/Gb-2007-8-7-R131 |
0.379 |
|
| 2007 |
Bloom GC, Eschrich S, Zhou JX, Coppola D, Yeatman TJ. Elucidation of a protein signature discriminating six common types of adenocarcinoma. International Journal of Cancer. Journal International Du Cancer. 120: 769-75. PMID 17131332 DOI: 10.1002/Ijc.22041 |
0.365 |
|
| 2006 |
Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 11-9. PMID 16397018 DOI: 10.1158/1078-0432.Ccr-04-1752 |
0.352 |
|
| 2005 |
Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, Cantor AB, Scuto A, Li C, Zhang S, Jove R, Yeatman T. Prediction of radiation sensitivity using a gene expression classifier. Cancer Research. 65: 7169-76. PMID 16103067 DOI: 10.1158/0008-5472.Can-05-0656 |
0.375 |
|
| 2005 |
Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhøffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3526-35. PMID 15908663 DOI: 10.1200/Jco.2005.00.695 |
0.335 |
|
| 2004 |
Eschrich S, Yeatman TJ. DNA microarrays and data analysis: an overview. Surgery. 136: 500-3. PMID 15349092 DOI: 10.1016/J.Surg.2004.05.038 |
0.31 |
|
| 2004 |
Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, Eschrich S, Quackenbush J, Yeatman TJ. Multi-platform, multi-site, microarray-based human tumor classification. The American Journal of Pathology. 164: 9-16. PMID 14695313 DOI: 10.1016/S0002-9440(10)63090-8 |
0.353 |
|
| Show low-probability matches. |